2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
The NEOSPHERE study showed that adding pertuzumab to trastuzumab (Herceptin) doubled the complete pathological response rate in the neoadjuvant stetting when it was combined with docetaxel.
Pertuzumab was also used in the APHINITY trial, results of which have not been published, but are indicating that pertuzumab provides some additional benefit in the adjuvant setting, says Osborne.